|
gptkbp:instanceOf
|
gptkb:chemical_compound
|
|
gptkbp:approvedBy
|
gptkb:leukemia
gptkb:chronic_myeloid_leukemia
|
|
gptkbp:ATCCode
|
L01EA02
|
|
gptkbp:CASNumber
|
gptkb:123441-03-2
|
|
gptkbp:contraindication
|
pregnancy
|
|
gptkbp:developedBy
|
gptkb:Bristol-Myers_Squibb
|
|
gptkbp:eliminationHalfLife
|
3-5 hours
|
|
gptkbp:excretion
|
urine
feces
|
|
gptkbp:hasInChIKey
|
KSRUEYVNCJQZEF-UHFFFAOYSA-N
|
|
gptkbp:hasMolecularFormula
|
C22H26ClN7O2S
|
|
gptkbp:hasSMILES
|
CC(C)[C@@H](NC(=O)C1=NN(C2=CC=CC=C21)C(=O)NC3=CC=CC=C3)C(=O)N
|
|
gptkbp:hasUNII
|
QIW9401TVU
|
|
gptkbp:isPatentProtected
|
yes
|
|
gptkbp:IUPACName
|
N-[(1S)-1-(Aminocarbonyl)-2-methylpropyl]-1,2-dihydro-3-oxo-2-phenyl-1H-pyrazole-4-carboxamide
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:marketedAs
|
gptkb:Sprycel
|
|
gptkbp:mechanismOfAction
|
gptkb:receptor_tyrosine_kinase
|
|
gptkbp:metabolism
|
liver (CYP3A4)
|
|
gptkbp:molecularWeight
|
488.98 g/mol
|
|
gptkbp:pregnancyCategory
|
D (US)
|
|
gptkbp:PubChem_CID
|
3062316
CHEMBL1421
DB01254
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
QT prolongation
fluid retention
myelosuppression
|
|
gptkbp:synonym
|
BMS-354825
Dasatinib
|
|
gptkbp:usedFor
|
gptkb:drug
|
|
gptkbp:bfsParent
|
gptkb:rivastigmine
|
|
gptkbp:bfsLayer
|
8
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
123441-03-2
|